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Abstract:  
The purpose of the study was to assess the effect of body weight on the course of COPD and asthma. Material and 
Methods: The clinical phase of the study was conducted on 113 patients with asthma and 264 patients with COPD. 
The patients were divided into 3 groups within their nosology depending on their BMI: with normal body weight (BMI: 
18.5-24.99), overweight (BMI: 25-29.99) and obesity (BMI: 30 or more). At the first stage of the study, an individual 
registration card was filled out for each patient. The symptoms of asthms and COPD were objectified by using a 10-
point visual analogue scale. To assess the severity of shortness of breath, a 4-point mMRC scale was used. The severity 
of symptoms of COPD and the impact of the disease on the daily activities of patients was assessed using the COPD 
Assessment Test. To assess the symptoms of COPD over the past week, a clinical questionnaire for COPD has been 
used - The Chronic obstructive pulmonary disease Control Questionnaire. To assess the degree of asthma control, an 
Asthma Control Test was used. The “Quality of Life for Asthma Patients” was used to assess the quality of life of 
patients with asthma, and for patients with COPD - Short Form Medical Outcomes Study 36. All patients underwent 
spirometry. The study of specific markers in blood serum was performed; in this research work have been analysed 
levels of leptin, adiponectin, the degree of total oxidative damage (TOD), the total antioxidant status (TOS), IL-4, IL-
6, TNF-α, neuropeptide Y. All received data were compared with the severity of clinical symptoms. The data were 
processed statistically using standard computer programs. The data obtained allow us to conclude that obesity as a 
source of chronic systemic inflammation is a predictor of the adverse course of asthma and COPD. To numerically 
determine the effect of obesity on these pulmonological pathologies, the following serum indices can be used: leptin, 
resistin, TNF-α. In addition, for asthma, in particular, neuropetid Y, the total oxidative damage and the total 
antioxidant status are promising markers. 
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INTRODUCTION: 
Asthma and chronic obstructive pulmonary disease 
(COPD) are the main issues of modern pulmonology, 
attracting scientists to search for methods of their 
prevention and treatment. In total, more than 500 
million people in the world suffer from asthma and 
COPD. (1.2) In recent years, the scientific community 
has been particularly interested in studying these 
pulmonary diseases in combination with concomitant 
pathology, including obesity. (3,4,5) 
 
The study of the combination of asthma with obesity 
was reflected in the formation of a new phenotype of 
the disease “asthma with obesity”, while the effect of 
body weight on COPD was considered in less detail. 
(6.7) However, the pathological processes connecting 
these two diseases are not completely known. (8) 
 
THE AIM OF THE STUDY:  
to assess the levels of leptin, asthmaiponectin, the 
degree of total oxidative damage (TOD), the total 
antioxidant status (TOS), IL-4, IL-6, TNF-α, 
neuropeptide Y, as well as the severity of clinical 
symptoms in patients with asthma and patients with 
COPD in various BMIs groups, and analyse the results 
when comparing with spirometry parameters. 
 
MATERIAL AND METHODS: 
The clinical part of the study was conducted on the 
basis of the general acute hospital №1 in Voronezh. 
Biochemical analyses were carried out on the basis of 
the Research Institute of Experimental Biology and 
Medicine of VSMU named after N. N. Burdenko of 
the Ministry of Health of Russia. 
 
For the final analysis, data were obtained on 113 
patients with asthma: 27 men and 86 women aged 18 
to 75 years (average age was 57.81 ± 13.05 years) and 
264 patients with COPD: 196 men aged 43 to 72 years 
(average age 63.94 ± 6.42 years) and 68 women from 
46 to 70 years (average age 60.66 ± 7.82 years). 
 
The diagnosis of asthma was masthmae in accordance 
with the criteria of the GINA 2018, the diagnosis of 
COPD was masthmae in accordance with the GOLD 
2017. 
 
Regarding the BMI parameter, all patients were 
divided into three groups within their nosology. Thus, 
the following groups were obtained: group 1 included 
patients with asthma and normal body weight (BMI: 
18.5-24.99), group 2 - with asthma and overweight 
(BMI: 25-29.99), 3 group - with asthma and obesity 
(BMI: 30 or more). Similarly, groups of patients with 
COPD were formed: group 1 - patients with a 
diagnosis of COPD and normal body weight (BMI: 
18.5-24.99), group 2 - with COPD and overweight 
(BMI: 25-29.99) , group 3 - with COPD and obesity 
(BMI: 30 or more). 
 
Exclusion criteria were the patient's refusal to 
participate in this study; exacerbation of asthma and 
COPD; acute and chronic neurological, psychiatric 
and endocrinological disorders at the time of 
examination; chronic diseases in the acute stage; 
severe and decompensated diseases of the liver and 
kidneys; severe and decompensated cardiovascular 
diseases (acute period of myocardial infarction, 
unstable angina, transient ischemic attack, 
intracerebral hemorrhage, acute heart failure, etc.); 
malignant neoplasms; multiple organ failure of 
various origins; pregnancy and lactation; severe 
infectious diseases. 
 
At the first stage of the study, an individual registration 
card was filled out for each patient. The symptoms of 
asthms and COPD were objectified by using a 10-
point visual analogue scale (VAS). To assess the 
severity of shortness of breath, a 4-point mMRC 
(modified Medical Research Council) scale was used. 
The severity of symptoms of COPD and the impact of 
the disease on the daily activities of patients was 
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assessed using the COPD Assessment Test (CAT). To 
assess the symptoms of COPD over the past week, a 
clinical questionnaire for COPD has been used - The 
Chronic obstructive pulmonary disease Control 
Questionnaire (CCQ). To assess the degree of asthma 
control, an Asthma Control Test (ACT) was used. The 
“Quality of Life for Asthma Patients” (international 
counterpart: Asthma Quality of Life Questionnaire - 
AQLQ) was used to assess the quality of life of 
patients with asthma, and for patients with COPD, a 
validated non-specific general short health status 
assessment questionnaire - Short Form Medical 
Outcomes Study 36 (SF-36). 
 
To conduct a spirometry study, a Diamant-S 
spirometer was used (CJSC “Diamant”, Russia). 
 
The study of specific markers in blood serum was 
performed on a “Multiskan Go” analyzer (Thermo 
Fisher Scientific, Finland). The tablet was washed 
using a tablet-washer for Wellwash enzyme-linked 
immunosorbent assay (Thermo Fisher Scientific, 
Finland), incubation (if necessary) using a PST-60HL-
4 thermal shaker (Biosan, Latvia). 
 
Statistical data processing was performed using the 
STATGRAPHICS 5.1 Plus for Windows software 
package. 
 
The study was approved by the Ethics Committee of 
Voronezh State Medical University named after N.N. 
Burdenko. Written informed consent was obtained 
from all patients participating in the study. 
 
RESULTS: 
The data obtained during the study show that 37 peo-
ple (asthma and normal body weight) were assigned in 
1 group of patients with asthma, the 2 group consisted 
of 38 people (asthma and overweight); Group 3 - 38 
people (asthma and obesity). Patients with COPD 
were divided as follows: group 1 - 88 patients (COPD 
with normal body weight), group 2 - 88 patients 
(COPD with overweight), group 3 - 88 patients 
(COPD and obesity). These study groups did not sig-
nificantly differ in a number of socio-demographic in-
dicators and, therefore, could be used for a compara-
tive assessment. 
 
Significant differences were revealed among the 
symptoms of asthma, the severity of which patients in-
dependently assessed according to the VAS scale be-
tween the three studied groups. 
 
Self-assessment of the cough severity was signifi-
cantly different in groups 2 and 1 (F = 8.34; p = 
0.0000), as well as 2 and 3 (F = 4.47; p = 0.0379), 
while between groups 1 and 3 significant differences 
were not detected (F = 0.41; p = 0.5218). Significant 
differences in the self-assessment of the severity of 
dyspnea were observed between groups 1 and 3 (F = 
4.09; p = 0.0467). When analyzing the self-assessment 
of the severity of viscous sputum among the three 
studied groups, there were no significant differences 
(F = 3.66; p = 0.0597), (F = 3.09; p = 0.0829), (F = 
0.14 ; p = 0.7070). Self-esteem of labored breathing 
significantly differed among patients of groups 1 and 
2 (F = 6.96; p = 0.0103), while differences between 
groups 1 and 3, as well as between groups 2 and 3 were 
not significant for this indicator ( F = 2.17; p = 
0.1456), (F = 0.82; p = 0.3684). 
 
According to the results of ACT in 3 groups of patients 
(patients with asthma and obesity), the level of disease 
control was significantly lower compared to group 2 
(overweight) (F = 6.04; p = 0.0165). There were no 
statistically significant differences between groups 3 
and 1, 2 and 1 (F = 3.67; p = 0.0594), (F = 0.90; p = 
0.3454). 
 
When analysing the quality of life of patients with 
asthma in all three groups (with normal, overweight 
and obesity), higher rates were noted in the domain of 
asthma symptoms (51.35 ± 14.06, 48.05 ± 8.35 and 47, 
61 ± 13.00 points, respectively), the domain of “activ-
ity limitations” (52.49 ± 13.54, 49.79 ± 11.08 and 
45.53 ± 12.14 points, respectively) and lower in the 
domains “emotional sphere ”(21.43 ± 19.9, 19.11 ± 
17.6, 19.13 ± 17.63 points, respectively), “environ-
mental impact ”(16.05 ± 6.78, 14.84 ± 3 , 61 and 13.68 
± 4.95 points, respectively). There were no statistically 
significant differences between groups with normal 
body weight, overweight and obesity in the domains 
of “asthma symptoms”, “activity restriction”, “emo-
tional sphere”, and “environmental impact” (F = 1.08; 
p = 0, 3439), (F = 3.07; p = 0.0506), (F = 1.52; p = 
0.2233), (F = 1.90; p = 0.1542). 
 
Spirometry study showed significant differences in 
bronchial obstruction in patients with asthma with dif-
ferent body weights. 
 
So, for instance, in the group of patients with asthma 
and normal body weight, the following indicators were 
significantly higher compared with the groups with 
overweight and obesity, which were: FEV1 - 89.30 ± 
23.27 (F = 7.42; p = 0, 0013), FVC - 104.10 ± 23.32 
(F = 9.19; p = 0.0004), VC - 93.08 ± 5.18 (F = 22.49; 
p = 0.0000). Significantly lower in the group of pa-
tients with asthma and overweight compared with 
groups with normal body weight and obesity was the 
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following indicators: FEV1/FVC - 76.87 ± 17.86 (F = 
7.46; p = 0.0011), MEF25, - 41.35 ± 30.42 (F = 6.36; 
p = 0.0029), MEF50 - 37.39 ± 32.68 (F = 4.13; p = 
0.0202), PEF - 15.12 ± 10.67 (F = 7.70; p = 0.0015). 
 
The average values of interleukin-4 were 6.32 ± 3.08 
pg / ml, 6.40 ± 3.51 pg / ml, 6.89 ± 5.40 pg / ml in 
groups 1, 2 and 3, respectively. Significant differences 
in the level of interleukin-4 in groups with normal 
body weight, overweight and obesity were not de-
tected (F = 0.21; p = 0.8085). The average values of 
interleukin-6 were 20.86 ± 13.93 pg / ml, 17.16 ± 9.16 
pg / ml, 14.92 ± 9.80 pg / ml in the first, second and 
third groups, respectively. The differences in the study 
groups for interleukin-6 were not significant (F = 2.71; 
p = 0.0708). 
 
The values of the TOS were 535.78 ± 64.35 μmol / L, 
277.59 ± 63.49 μmol / L and 287.96 ± 63.49 μmol / L 
in the first, second and third groups, respectively. The 
value of the TOS characterizing the antioxidant activ-
ity of the body was significantly higher in the first 
group of patients compared with the second and third 
groups (F = 5.21; p = 0.0069). 
The values of the TOD to the molecules were 877.70 
± 623.33 μmol / L, 1177.75 ± 1022.51 μmol / L and 
1454.69 ± 1257.72 μmol / L in the first, second 
 
and third groups, respectively. The values of this indi-
cator in the first group of patients were significantly 
lower than in the third group (F = 3.09; p = 0.0496). 
 
The level of TNF-α was significantly lower in group 2 
(1.78 ± 0.35 pg / ml) compared with the 1 (2.01 ± 0.31 
pg / ml) and 3 (2.03 ± 0.37 pg / ml) by groups (F = 
8.69; p = 0.0043), (F = 8.97; p = 0.0037), respectively. 
There were no statistically significant differences in 
the level of TNF-α between the first and third groups 
(F = 0.08; p = 0.7821). 
The level of neuropeptide Y was 0.31 ± 0.02 ng / ml 
in the first group, 0.48 ± 0.02 ng / ml in the second 
group, 1.19 ± 0.25 ng / ml in the third group of pa-
tients. The value of neuropeptide Y was significantly 
lower in group 1 with normal body weight compared 
with group 2 with overweight and group 3 with obesity 
(F = 36.69; p = 0.0000), (F = 8.97 ; p = 0.0037). There 
were no statistically significant differences in the level 
of neuropeptide Y between the second and third 
groups (F = 0.08; p = 0.7821). 
 
The leptin level was significantly higher in group 3 
(patients with asthma and obesity) compared with 
group 1 (patients with asthma and normal body 
weight) and group 2 (patients with asthma and over-
weight) and amounted to 13.01 ± 1.97 , 11.32 ± 1.99 
and 22.36 ± 1.97 ng / ml, respectively (F = 9.06; p = 
0.0002). The adiponectin level was 23.66 ± 11.03 μg / 
ml in the first group, 23.40 ± 11.29 μg / ml in the sec-
ond group and 23.70 ± 10.25 μg / ml in the third group 
of the studied. There were no statistically significant 
differences in adiponectin levels in groups with nor-
mal body weight, overweight and obesity (F = 0.01; p 
= 0.9915). The resistin level was 5.40 ± 2.63, 5.83 ± 
2.42 and 6.86 ± 3.36 in the first, second and third 
group of patients, respectively. Differences in resistin 
levels in the study groups were statistically significant 
(F = 3.61; p = 0.0384). 
 
In patients with COPD and obesity, the severity of 
dyspnea, sputum production and general weakness ac-
cording to VAS was significantly lower compared to 
patients with COPD and normal body weight. (F = 
25.33, p = 0.0000), (F = 5.80, p = 0.0170), (F = 8.52, 
p = 0.0040) and amounted to 7.14 ± 2.32 , 3.97 ± 1.86 
and 6.66 ± 2.06 points, respectively. With a compara-
tive characteristic of the severity of symptoms in pa-
tients with COPD and overweight, the severity of 
dyspnea according to VAS was significantly lower 
compared with patients with COPD and normal body 
weight and amounted to 8.0 ± 1.72 and 8.60 ± 1.44 
points, respectively (F = 6.32, p = 0.0128). There were 
no statistically significant differences between the 
groups in terms of VAS cough, VAS sputum, VAS 
weakness (F = 0.24, p = 0.6274), (F = 1.24, p = 
0.2664), (F = 2, 36, p = 0.1267). 
 
When analysing the parameters of spirometry, indica-
tors such as FEV1, FVC and FEV1/FVC in patients 
with COPD and obesity, as well as in patients with 
COPD and overweight, were significantly higher than 
in patients with COPD with normal body weight (F = 
39.78, p = 0.0000), (F = 38.54, p = 0.0000), (F = 24.80, 
p = 0.0000) for comparing groups 1 and 3, and (F = 
10.13, p = 0.0017), (F = 5.60, p = 0.0191), (F = 23.18, 
p = 0.0000) for comparing 1 and 2. 
Based on the results of spirometry, groups 1 and 3 also 
significantly differed in the distribution of patients ac-
cording to the degree of bronchial obstruction (GOLD 
1, 2, 3, 4) (χ2 = 58.76; p = 0.0000; Kendall's Tau b -
0.4347 , p = 0.0000). 
 
Since the value of the Kendall's Tau b coefficient was 
negative at a significance level of p <0.05, among pa-
tients with COPD and obesity, patients with a degree 
of bronchial obstruction GOLD 2 and 3 were signifi-
cantly more likely than among patients with COPD 
and normal body weight (31 (35 , 23%) and 50 
(56.82%), compared with 17 (19.31%) and 16 
(18.18%), respectively). And vice versa - among pa-
tients with COPD and normal body weight, patients 
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with a degree of bronchial obstruction GOLD 4 (55 
(62.5%) and 7 (7.9%), respectively) were significantly 
more likely to prevail. There were no patients with the 
degree of bronchial obstruction GOLD 1 in the study 
groups. There were no significant differences between 
the studied groups 1 and 3 in the distribution of pa-
tients with belonging to patient groups A, B, C, D (χ2 
= 1.43; p = 0.2316). 
 
Similar results were obtained when comparing the re-
sults of spirometry in groups 1 and 2 (GOLD 1, 2, 3, 
4) (χ2 = 34.26; p = 0.0000; Kendall's Tau b -0.3596, p 
= 0.0000). Among patients with COPD and over-
weight, patients with a degree of bronchial obstruction 
GOLD 2 and 3 were significantly more common than 
among patients with COPD and normal body weight 
(32 (36.36%) and 39 (44.31%), compared with 17 ( 
19.31%) and 16 (18.18%), respectively). And, on the 
contrary, among patients with COPD and normal body 
weight, patients with a degree of bronchial obstruction 
GOLD 4 (55 (62.5%) and 17 (19.31%), respectively) 
were significantly more likely to prevail. There were 
no patients with the degree of bronchial obstruction 
GOLD 1 in the study groups. Groups 1 and 2 also sig-
nificantly differed in the distribution of patients by be-
longing to patient groups A, B, C, D (χ2 = 8.123; p = 
0.0044; Kendall's Tau b -0.2148, p = 0.0045). Since 
the value of the Kendall's Tau b coefficient was nega-
tive at a significance level of p <0.05, among patients 
with COPD and overweight, group B patients were 
significantly more likely to occur than among patients 
with COPD and normal body weight (16 (18.18%) and 
4 (4.54%), respectively). And vice versa - among pa-
tients with COPD and normal body weight, group D 
patients were more common than group 2 (84 
(95.45%) and 72 (81.81%), respectively). There were 
no patients of groups A and C in the studied groups. 
 
We obtained data on a statistically significant higher 
quality of life in patients with COPD and normal body 
weight compared to patients with COPD and obesity 
according to the SF-36 scales, which are defined as the 
physical component of health (role functioning due to 
physical condition, which amounted to 35.39 ± 21.59 
and 24.24 ± 11.36 points, respectively (F = 5.00, p = 
0.0266), the intensity of pain, which was 70.39 ± 39.06 
and 56.61 ± 29.31 points, respectively (F = 7.00, p = 
0.0089), the general state of health, which was 38.55 
± 11.14 and 34.72 ± 14.32 points, respectively (F = 
3.92, p = 0, 04 93)), as well as the psychological com-
ponent of health (vital activity, which was 43.69 ± 
14.94 and 38.23 ± 12.15 points, respectively (F = 7.06, 
p = 0.0086)). 
 
There were no statistically significant differences in 
the level of IL-4 between 1, 2 and 3 groups of patients 
with COPD. As in the level of IL-6 between groups 1 
and 3. As for the comparison of groups 1 and 2, the 
level of IL-6 was significantly higher in the group of 
patients with COPD and overweight than in patients 
with COPD and normal body weight 32.36 (8.59; 
44.81) and 22 , 31 
 
(4.877; 40.85), respectively (p = 0.0397). Compared to 
patients with COPD and normal body weight, patients 
with COPD and obesity had significantly higher levels 
of TNF-α (0.001 (0.001; 0.3507) and 0.001 (0.001; 
0.001) pg / ml, respectively (p = 0.0189)). When com-
paring the levels of TNF-α in group 1 and 2, the fol-
lowing values were obtained: (0.001 (0.001; 0.5967) 
and 0.001 (0.001; 0.001) pg / ml, respectively (p = 
0.0082). 
 
We found that the level of leptin in patients with 
COPD and obesity, as well as patients with COPD and 
overweight compared with patients with COPD and 
normal body weight, was significantly higher (45.58 ± 
29.47 and 13.32 ± 10.81 ng / ml, (F = 92.92, p = 
0.0000)), (24.05 ± 19.69 and 13.32 ± 10.81 ng / ml, (F 
= 20.08, p = 0.0000 )) respectively. There were no sta-
tistically significant differences in adiponectin level 
between groups 1 and 3, 1 and 2 (F = 2.41, p = 0.1223), 
(F = 1.21, p = 0.2726). Also, the resistin level did not 
have significant differences in groups 1 and 3 (F = 
0.01, p = 0.9133), but was significantly lower (7.85 ± 
3.90 and 9.54 ± 5.94 ng / ml, respectively (F = 4.94, p 
= 0.0276) in patients with overweight and COPD to 
compared with patients with COPD and normal body 
weight. 
 
THE DISCUSSION OF THE RESULTS: 
Thus, reliable relationships between the presence of 
obesity in asthma patients and the following indicators 
in the blood serum were revealed: the level of anorex-
igenic neuropetide Y, which causes insulin resistance 
- resistin, the level of TNF-α, the indicator of antioxi-
dant activity of the body, and the degree of oxidative 
damage to biomolecules. As for patients with COPD, 
a relationship was found between obesity in these pa-
tients and the following indicators: levels of IL-6, 
TNF-α, leptin and resistin. 
 
According to GINA (2019), obesity is a state of mild 
chronic inflammation with increased pro-inflamma-
tory activity caused by adipocytes. Adipokines are se-
creted by adipose tissue cells, leptin and adiponectin 
are some examples of such adipokines, the effect of 
which on the course of asthma and COPD continues to 
be studied. Leptin is a pro-inflammatory cytokine and 
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may be one of the factors contributing to an increase 
in the prevalence of asthma and COPD in obese pa-
tients. It stimulates the release of NO, IL-6 and IL-8 
and TNF-α. (9) There are already studies in which it 
was proven that the experimental administration of 
TNF-α to mice increased leptin levels. (10) Higher lep-
tin levels are recorded in patients with asthma; this is 
more clearly seen in women than in men, and more 
pronounced in premenopausal women than in post-
menopausal women. In turn, adiponectin plays the op-
posite role, inhibiting inflammation. 
 
Our study also showed that adiponectin acts as an in-
hibitor of inflammation in asthma, since it has a posi-
tive correlation with spirometry parameters. Data on 
the relationship between asthma and adiponectin are 
contradictory. Some studies suggest that low adi-
ponectin levels are more likely to cause asthma in 
women (11), while others generally deny any correla-
tion. (12) Other studies report that higher adiponectin 
levels correlate with mild asthma, but only in women, 
while in men, this relationship is the opposite: asthma, 
which requires more active drug support, has been as-
sociated with higher adiponectin. (13) A study was 
also conducted that analysed serum adiponectin levels 
and adiponectin mRNA expression in abdominal adi-
pose tissue in obese patients. Obese and asthma pa-
tients had lower 
adiponectin mRNA expression than obese patients 
without asthma, but serum adiponectin levels did not 
differ significantly in these groups. (14) There is also 
information about a decrease in serum adiponectin, but 
only during exacerbations in asthma patients. These 
data suggest that a decrease in adiponectin may not be 
a predictor, but a consequence of the clinical course of 
asthma. 
 
Oxidative stress plays an important role in the patho-
genesis of asthma. According to recent studies, bi-
omarkers of oxidative stress are higher in obese pa-
tients and correlate with BMI (15), while biomarkers 
of antioxidant defense are inversely correlated. In our 
study, we observed the same relationship in patients 
with asthma with different body weights. As for infor-
mation on neuropeptide Y, the available scientific data 
on the relationship between neuropeptide Y and 
asthma are ambiguous. Several studies have reported 
that certain genotypes of neuropeptide Y are associ-
ated with asthma. (16) Y1 receptors of neuropeptide Y 
play an important role in allergic inflammation of res-
piratory airways. One study also reports that during 
exacerbations of asthma, neuropeptide Y levels in-
crease. In our study, neuropeptide Y levels were sig-
nificantly higher in obese and overweight patients with 
asthma and had an inverse correlation with spirometry 
parameters, which indicates a negative effect on the 
clinical course of asthma. Therefore, it can be said that 
the severity of the clinical course of asthma in obese 
patients is associated with various factors, including 
oxidative stress and levels of leptin, adiponectin, and 
neuropeptide Y. Although the exact mechanisms re-
main unclear. 
Conclusion: the data obtained allow us to conclude 
that obesity as a source of chronic systemic inflamma-
tion is a predictor of the adverse course of asthma and 
COPD. To numerically determine the effect of obesity 
on these pulmonological pathologies, the following se-
rum indices can be used: leptin, resistin, TNF-α. In ad-
dition, for asthma, in particular, neuropetid Y, the total 
oxidative damage and the total antioxidant status are 
promising markers. 
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